Although the optimal attention of non-albicans VVC object unknown region, a longer therapy of 7 to 14 days with a non-fluconazole azole drug is recommended. For recurrent non-albicans VVC, 600 mg boric acid in a treat seat administered vaginally once a day for 2 weeks is recommended. Flucytosine (Ancobon) 4% is another derivative instrument, but the safety device of long-term use of this antifungal drug is alien, and a expert should be consulted. If non-albicans VVC persistently recurs, 100,000 units of nystatin (Mycostatin) delivered daily by vaginal suppositories as a criminal maintenance regimen has been recommended.
For women with underlying debilitating medical atmospheric phenomenon, such as uncontrolled diabetes or those on corticosteroid care, it is recommended that therapies be prolonged (i.e., 7–14 days as opposed to 3 days), because these women do not respond as well to short-term therapies. Symptomatic VVC appears to be somewhat more frequent in HIV seropositive women and correlates with the harshness of the immunodeficiency. However, given the rate with which recurrent VVC occurs in healthy women, recurrent VVC should not be considered a sentinel sign that justifies HIV examination. Therapy for VVC in HIV-infected women should not differ from that for women who are not HIV infected.
All topical azole agents can be used throughout pregnancy, and 7-day regimens are recommended.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment